Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
About this item
Full title
Author / Creator
Martins, Filipe , Sofiya, Latifyan , Sykiotis, Gerasimos P. , Lamine, Faiza , Maillard, Michel , Fraga, Montserrat , Shabafrouz, Keyvan , Ribi, Camillo , Cairoli, Anne , Guex-Crosier, Yan , Kuntzer, Thierry , Michielin, Olivier , Peters, Solange , Coukos, Georges , Spertini, Francois , Thompson, John A. and Obeid, Michel
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for these agents continue to expand across malignancies a...
Alternative Titles
Full title
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2232036420
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2232036420
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/s41571-019-0218-0
